Last reviewed 2026-04-20 · How we verify

Ponalide (etybenzatropine)

Ponalide (generic name: etybenzatropine) is a etybenzatropine drug. It is currently in unknown development.

Ponalide works by blocking the action of acetylcholine, a neurotransmitter that helps transmit signals in the brain and nervous system.

Ponalide, also known as etybenzatropine, is a small molecule drug in the drug class of anticholinergics. Its exact target is unknown, but it is believed to work by blocking the action of acetylcholine, a neurotransmitter involved in various bodily functions. Ponalide is not FDA-approved for any indications, and its commercial status is unclear. As an anticholinergic, it may be used off-label to treat conditions such as Parkinson's disease or other movement disorders. However, its safety and efficacy in these contexts are not well-established.

At a glance

Mechanism of action

Think of acetylcholine like a messenger that helps different parts of your body talk to each other. When acetylcholine is released, it sends a signal to a muscle or gland to do something, like move or sweat. Ponalide blocks these signals, which can help reduce muscle spasms or other symptoms in certain conditions.

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

• Ponalide CI brief — competitive landscape report
• Ponalide updates RSS · CI watch RSS
• portfolio CI

Frequently asked questions about Ponalide

Related

• Drug class: All etybenzatropine drugs
• Manufacturer: — full pipeline
• Therapeutic area: All drugs in Neuroscience

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing